Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 15/20 | 0.63 |
| ▸ | ABL1 | P00519 | 14/20 | 0.63 |
| ▸ | ABL2 | P42684 | 9/20 | 0.63 |
| ▸ | LDLR | P01130 | 3/20 | 0.55 |
| ▸ | PCSK9 | Q8NBP7 | 3/20 | 0.55 |
| ▸ | LYN | P07948 | 2/20 | 0.54 |
| ▸ | BCR | P11274 | 2/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29551545 | 1.00 | KIT (0.63) | KITABL1ABL2LDLRPCSK9 | |
| SCHEMBL24250905 | 0.89 | KIT (0.61) | KITABL1ABL2LDLRPCSK9 | |
| SCHEMBL29551572 | 0.89 | KIT (0.61) | KITABL1ABL2LDLRPCSK9 | |
| SCHEMBL29551829 | 0.89 | KIT (0.74) | KITABL1ABL2LDLRPCSK9 | |
| SCHEMBL24251063 | 0.89 | KIT (0.74) | KITABL1ABL2LDLRPCSK9 | |
| SCHEMBL24250972 | 0.89 | ABL1 (0.60) | KITABL1ABL2LYNBCR | |
| SCHEMBL29551734 | 0.89 | ABL1 (0.60) | KITABL1ABL2LYNBCR | |
| SCHEMBL24251154 | 0.88 | ABL1 (0.69) | KITABL1ABL2LDLRPCSK9 | |
| SCHEMBL29551226 | 0.88 | ABL1 (0.69) | KITABL1ABL2LDLRPCSK9 | |
| SCHEMBL24250995 | 0.88 | ABL1 (0.66) | KITABL1ABL2LDLRPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114127065-A | Compounds for the treatment of neurodegenerative diseases and cancer | 鸿仪有限责任公司 | 2022-03-01 | — | — | CN | claimed |
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | HONGYI & ASS LLC (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | SNCA, NGF, SLC18A2 | KIT 2333/4885ABL1 695/4885ABL2 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.